ANAPTYSBIO, INC. Interest Expense
ANAPTYSBIO, INC. (ANAB) reported Interest Expense of $0 for the 12-month period ending 2021-12-31, per its 10-K filed 2022-03-07.
Discontinued › Expense Statement
us-gaap:InterestExpense · last filed 2022-03-07
- ANAPTYSBIO, INC. interest expense for the quarter ending 2020-12-31 was $0.00, a 100.00% decline year-over-year.
- ANAPTYSBIO, INC. interest expense for the quarter ending 2020-09-30 was $0.00, a 100.00% decline year-over-year.
- ANAPTYSBIO, INC. interest expense for the quarter ending 2020-06-30 was $0.00, a 100.00% decline year-over-year.
- ANAPTYSBIO, INC. interest expense for the quarter ending 2020-03-31 was $0.00, a 100.00% decline year-over-year.
- ANAPTYSBIO, INC. interest expense for fiscal 2021 was $0.00.
- ANAPTYSBIO, INC. interest expense for fiscal 2020 was $0.00, a 100.00% decline from fiscal 2019.
- ANAPTYSBIO, INC. interest expense for fiscal 2019 was $1.04M, a 36.99% decline from fiscal 2018.
- ANAPTYSBIO, INC. interest expense for fiscal 2018 was $1.65M, a 6.93% decline from fiscal 2017.
| Period end | Interest Expense 3 month | Interest Expense 6 month | Interest Expense 9 month | Interest Expense 12 month |
|---|---|---|---|---|
| 2021-12-31 | $0.00 10-K · filed 2022-03-07 | |||
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-07 | $0.00 derived: sum of 2 quarters · filed 2022-03-07 | $0.00 derived: sum of 3 quarters · filed 2022-03-07 | $0.00 10-K · filed 2022-03-07 |
| 2020-09-30 | $0.00 10-Q · filed 2020-11-04 | $0.00 derived: sum of 2 quarters · filed 2020-11-04 | $0.00 10-Q · filed 2020-11-04 | $200.00K derived: sum of 4 quarters · filed 2022-03-07 |
| 2020-06-30 | $0.00 10-Q · filed 2020-08-10 | $0.00 10-Q · filed 2020-08-10 | $200.00K derived: sum of 3 quarters · filed 2022-03-07 | $440.00K derived: sum of 4 quarters · filed 2022-03-07 |
| 2020-03-31 | $0.00 10-Q · filed 2020-05-06 | $200.00K derived: sum of 2 quarters · filed 2022-03-07 | $440.00K derived: sum of 3 quarters · filed 2022-03-07 | $721.00K derived: sum of 4 quarters · filed 2022-03-07 |
| 2019-12-31 | $200.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-07 | $440.00K derived: sum of 2 quarters · filed 2022-03-07 | $721.00K derived: sum of 3 quarters · filed 2022-03-07 | $1.04M 10-K · filed 2022-03-07 |
| 2019-09-30 | $240.00K 10-Q · filed 2020-11-04 | $521.00K derived: sum of 2 quarters · filed 2020-11-04 | $841.00K 10-Q · filed 2020-11-04 | $1.21M derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-06-30 | $281.00K 10-Q · filed 2020-08-10 | $601.00K 10-Q · filed 2020-08-10 | $966.00K derived: sum of 3 quarters · filed 2021-02-25 | $1.37M derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-03-31 | $320.00K 10-Q · filed 2020-05-06 | $685.00K derived: sum of 2 quarters · filed 2021-02-25 | $1.08M derived: sum of 3 quarters · filed 2021-02-25 | $1.52M derived: sum of 4 quarters · filed 2021-02-25 |
| 2018-12-31 | $365.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $765.00K derived: sum of 2 quarters · filed 2021-02-25 | $1.20M derived: sum of 3 quarters · filed 2021-02-25 | $1.65M 10-K · filed 2021-02-25 |
| 2018-09-30 | $400.00K 10-Q · filed 2019-11-08 | $836.00K derived: sum of 2 quarters · filed 2019-11-08 | $1.29M 10-Q · filed 2019-11-08 | $1.74M derived: sum of 4 quarters · filed 2020-03-02 |
| 2018-06-30 | $436.00K 10-Q · filed 2019-08-08 | $887.00K 10-Q · filed 2019-08-08 | $1.34M derived: sum of 3 quarters · filed 2020-03-02 | $1.79M derived: sum of 4 quarters · filed 2020-03-02 |
| 2018-03-31 | $451.00K 10-Q · filed 2019-05-07 | $907.00K derived: sum of 2 quarters · filed 2020-03-02 | $1.36M derived: sum of 3 quarters · filed 2020-03-02 | $1.80M derived: sum of 4 quarters · filed 2020-03-02 |
| 2017-12-31 | $456.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-02 | $908.00K derived: sum of 2 quarters · filed 2020-03-02 | $1.35M derived: sum of 3 quarters · filed 2020-03-02 | $1.77M 10-K · filed 2020-03-02 |
| 2017-09-30 | $452.00K 10-Q · filed 2018-11-08 | $891.00K derived: sum of 2 quarters · filed 2018-11-08 | $1.32M 10-Q · filed 2018-11-08 | $1.43M derived: sum of 4 quarters · filed 2019-02-28 |
| 2017-06-30 | $439.00K 10-Q · filed 2018-08-07 | $867.00K 10-Q · filed 2018-08-07 | $978.00K derived: sum of 3 quarters · filed 2019-02-28 | $1.09M derived: sum of 4 quarters · filed 2019-02-28 |
| 2017-03-31 | $428.00K 10-Q · filed 2018-05-08 | $539.00K derived: sum of 2 quarters · filed 2019-02-28 | $655.00K derived: sum of 3 quarters · filed 2019-02-28 | $771.00K derived: sum of 4 quarters · filed 2019-02-28 |
| 2016-12-31 | $111.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-28 | $227.00K derived: sum of 2 quarters · filed 2019-02-28 | $343.00K derived: sum of 3 quarters · filed 2019-02-28 | $458.00K 10-K · filed 2019-02-28 |
| 2016-09-30 | $116.00K 10-Q · filed 2017-11-07 | $232.00K derived: sum of 2 quarters · filed 2017-11-07 | $347.00K 10-Q · filed 2017-11-07 | |
| 2016-06-30 | $116.00K 10-Q · filed 2017-08-10 | $231.00K 10-Q · filed 2017-08-10 | ||
| 2016-03-31 | $115.00K 10-Q · filed 2017-05-12 | |||
| 2015-12-31 | $460.00K 10-K · filed 2018-03-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |